文献速递泌尿男性生殖肿瘤

CXCL13作为三级淋巴结构标志物与晚期膀胱癌免疫治疗生存获益相关

Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
PubMed 文献 · Eur J Cancer · 2021-03-18

本研究基于三个公开MIBC队列的转录组数据,评估CXCL13表达对ICI治疗的预后价值,并对TCGA-BLCA病理切片评估TLS存在与成熟阶段。结果显示CXCL13独立关联ICI治疗患者的总生存延长(HR=0.8,95%CI 0.68-0.94)和客观缓解(p<0.0001),且与肿瘤TLS相关(p<0.001),支持其作为晚期膀胱癌ICI反应的候选预测生物标志物。

要点

  • CXCL13高表达与ICI治疗MIBC患者生存延长独立相关(HR=0.8,95%CI 0.68-0.94)。
  • CXCL13与ICI治疗的客观缓解显著相关(p<0.0001),其他免疫特征无此关联。
  • CXCL13在非ICI治疗MIBC中无预测作用,提示其预测ICI疗效的特异性。

核心结论

  • CXCL13表达作为肿瘤TLS的替代标志物,是晚期膀胱癌患者ICI反应的候选预测生物标志物。

研究设计与样本

  • 分析三个公开MIBC队列的转录组数据,并对TCGA-BLCA队列病理切片评估TLS存在与成熟阶段。

主要发现

  • CXCL13独立关联ICI治疗患者的生存延长(HR=0.8,95%CI 0.68-0.94)。
  • CXCL13与ICI治疗的客观缓解相关(p<0.0001),而其他免疫特征无此关联。
  • CXCL13在非ICI治疗MIBC中不是预测因子,提示其预测ICI疗效的作用。
  • CXCL13表达与TCGA数据集中的肿瘤TLS相关(p<0.001),可作为膀胱癌TLS标志物。

临床怎么用

  • CXCL13表达或可作为筛选晚期膀胱癌ICI治疗获益人群的候选生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Immune checkpoint inhibitors (ICIs) have proved to be an effective treatment for up to 40% of muscle-invasive bladder cancer (MIBC), but there is still a need for better performing biomarkers allowing to improve prediction of response to ICI. Response to immunotherapy in soft-tissue sarcoma, melanoma and renal cell carcinoma have been recently linked to the presence of tertiary lymphoid structures (TLS) in the tumour. TLS are organised aggregates of T, B and dendritic cells, participating in adaptive antitumor immune response. The chemokine CXCL13 is involved in the formation of TLS, and is reported as a reliable transcriptomic marker of TLS. OBJECTIVES: In this study, we sought to assess whether CXCL13 transcript expression can be a prognostic biomarker for ICI-treated MIBC patients and also investigated whether it can serve a biomarker of TLS in MIBC. METHODS: We analysed transcriptomic data from three publicly available MIBC cohorts and evaluated pathological slides from the TCGA-BLCA cohort for TLS presence and stage of maturation. RESULTS: We showed that CXCL13 was independently associated with both prolonged survival (HR = 0.8, 95% CI [0.68-0.94]) and objective response (p < 0.0001) in patients treated with ICI, at the difference of others immunological signatures. However, it was not a predictor for non-ICI-treated MIBC, suggesting a predictive effect of ICI efficacy. Finally, we validated that CXCL13 expression was correlated with tumour TLS in TCGA data set (p < 0.001), and can serve as a marker of TLS in bladder cancer. CONCLUSION: These results support that CXCL13 expression, as a surrogate for tumour TLS, is a relevant candidate predictive biomarker of response to ICI for patients with advanced-stage bladder cancer.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Groeneveld CS, Fontugne J, Cabel L, et al. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. Eur J Cancer. 2021. PMID: 33743486. doi:10.1016/j.ejca.2021.01.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。